Cardinal Health, Inc. (CAH) is an American multinational health care services company that provides a broad range of services to pharmacies, hospitals, ambulatory surgery centers, clinical laboratories, and physician offices globally. The company's operations are divided into two segments: Pharmaceutical and Medical, each carrying out various specialized activities.
The Pharmaceutical segment distributes a vast range of national brand, generic pharmaceuticals, specialty pharmaceuticals, and over-the-counter healthcare and consumer products in the United States. They operate the world's largest network of nuclear pharmacies and are expanding their positron emission tomography (PET) radiopharmaceutical dispensing network to meet the growing needs of health care providers.
The Medical segment manufactures, sources, and distributes Cardinal Health's label medical, laboratory, and surgical products and services through hospital direct, integrated delivery networks, independent healthcare distributors, and the company's e-commerce platform, cardinal.com.
Established in 1971, Cardinal Health has its headquarters in Dublin, Ohio. As of today, it ranks 16th on the Fortune 500 list and is regarded as one of the highest revenue-generating companies in the United States. Over the years, the company has acquired numerous businesses, significantly broadening its scope and capabilities.
Cardinal Health works with stakeholders to make healthcare safer while ensuring costs are effectively managed for its approximately 100 million customers. The company provides clinically proven medical products, pharmaceuticals, and cost-effective solutions that enhance supply chain efficiency from hospital to home.
Key to Cardinal Health's business model is their commitment to transform healthcare with innovative solutions. Their expertise in pharmaceutical distribution and supply chain management allows them to address unique challenges in healthcare delivery. With nearly 50,000 employees worldwide, Cardinal Health is essential in making healthcare more efficient, thereby helping customers thrive in a changing world.
In summary, Cardinal Health, Inc. (CAH) is a crucial player in the global healthcare sector with a relentless commitment to delivering value to clients while advancing health and wellness for people around the world.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article compares AbbVie and Pfizer, two pharmaceutical giants, for investors looking at 2026. AbbVie is transitioning its focus to newer immunology drugs, while Pfizer is pursuing aggressive acquisitions in oncology and metabolic assets to counter post-pandemic revenue declines and upcoming patent expirations. While both offer significant dividends, Pfizer appears to be the more undervalued stock based on current valuation metrics, despite AbbVie's promising pipeline.
This article compares AbbVie and Pfizer, two pharmaceutical giants, for investors in 2026, analyzing their financial performance, product pipelines, and risk profiles. While AbbVie is transitioning from its Humira era with new immunology leaders, Pfizer is focusing on oncology and metabolic assets through acquisitions, navigating post-pandemic changes and patent expirations. The author ultimately suggests Pfizer is currently undervalued despite AbbVie's promising pipeline, due to Pfizer's lower valuation metrics and recent growth in its oncology business.
McKesson (MCK) recently raised its full-year adjusted EPS guidance, leading to investor reassessment despite a recent share price dip. While the stock has seen strong long-term gains, short-term momentum has cooled, prompting questions about its current valuation. Analysts, based on a "most followed view," suggest McKesson is still 11% undervalued, with a fair value of $980.73, driven by its focus on oncology and access platforms.
Cardinal Health Inc. (CAH) stock declined by 1.08% on Friday, closing at $220.22, despite an overall positive trading session for the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw gains. The company's stock is currently trading 14.74% below its 52-week high achieved on August 11th.
This article compares Cardinal Health (CAH) and McKesson (MCK), two major players in U.S. pharmaceutical distribution. While both are positioned for growth and leverage specialty pharmaceuticals and technology, Cardinal Health shows stronger earnings momentum, better valuation, and a more favorable estimate revision trend. McKesson, despite its scale and specialty services, exhibits less valuation differentiation and a weaker momentum score.
The article compares Cardinal Health (CAH) and McKesson (MCK), two direct competitors in U.S. pharmaceutical distribution, evaluating their recent performance, growth strategies, and valuation. It concludes that while both are strong companies, CAH currently presents a more compelling investment due to its stronger projected EPS growth, favorable valuation, and estimate momentum, despite both holding a Zacks Rank #3 (Hold).
GE HealthCare (GEHC) stock has fallen 28% from its high due to headwinds like stalled sales in China, import tariffs, and tight hospital budgets. Despite this, Wall Street is beginning to buy, with Needham initiating a "Buy" rating and a $93 price target, citing attractive valuation and strong demand for imaging equipment. The company's future hinges on whether its China market share losses and tariff impacts are temporary or long-term, alongside the potential acquisition of Sofie Biosciences.
GE HealthCare (GEHC) has seen a 28% decline, prompting Needham to initiate coverage with a "Buy" rating and a $93 target, citing attractive valuation. The selloff is attributed to stalled sales in China due to competition and budget constraints, as well as tariffs. However, bulls point to essential imaging demand, AI integration, recurring revenue, and a potential acquisition, while bears remain cautious about China market share losses and unpredictable costs.
Cardinal Health Inc. (CAH) stock declined by 1.64% on Tuesday, closing at $222.04, while the broader market showed mixed results with the S&P 500 largely unchanged and the Dow Jones Industrial Average falling. The company's stock is currently trading 14.04% below its 52-week high of $258.30, achieved on August 11th.